[{"title":"The Virtual CVOT Summit 2022 will start on November 10 at 16:00 CET.","time":"","speaker":"","day":0,"start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":0,"start":"","minutes":"999999999999999"},{"title":"The livestream will start today at 16:00 CET.","time":"","speaker":"","day":0,"start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":0,"start":"","minutes":"999999999999999"},{"title":"Welcome and Introduction","time":"16:00 \u2013 16:10 CET","speaker":"Schnell O (Munich, Germany)","day":"do","start":"16:00:00","minutes":0},{"title":"Update on CVD, HF, and CKD Treatment: The ADA-EASD Consensus Report 2022","time":"16:10 \u2013 16.25 ","speaker":"Mathieu C (Leuven, Belgium)","day":"do","start":"16:10:00","minutes":10},{"title":"New pharmacotherapies for Type 2 Diabetes: a systematic review and network meta-analysis of randomised controlled trials","time":"16:25 \u2013 16:40 ","speaker":"Mustafa R (Kansas City, US)","day":"do","start":"16:25:00","minutes":25},{"title":"Diabetes and CVD: achieving guideline-recommended management  at 12 months ","time":"16:40 \u2013 16:55","speaker":"Green J (Durham, US)) ","day":"do","start":"16:40:00","minutes":40},{"title":"Discussion","time":"16:55 \u2013 17:10 ","speaker":"","day":"do","start":"16:55:00","minutes":55},{"title":"Early Clinical Studies: Paving the road for outcomes trials in diabetes","time":"17:10 \u2013 17:30","speaker":"Hompesch M (San Diego, US)","day":"do","start":"17:10:00","minutes":70},{"title":"Discussion","time":"17:30 \u2013 17:40","speaker":"","day":"do","start":"17:30:00","minutes":90},{"title":"Subtypes of Type 2 Diabetes \u2013 Shaping cardiovascular risk","time":"17:40 \u2013 18:00","speaker":"Birkenfeld A (Tuebingen, Germany)","day":"do","start":"17:40:00","minutes":100},{"title":"Discussion","time":"18:00 \u2013 18:10 ","speaker":"","day":"do","start":"18:00:00","minutes":120},{"title":"CGM for changing Type 2 Diabetes medication","time":"18:10 \u2013 18:30 ","speaker":"Bergenstal R (Minneapolis, US) ","day":"do","start":"18:10:00","minutes":130},{"title":"Discussion","time":"18:30 \u2013 18:40 ","speaker":"","day":"do","start":"18:30:00","minutes":150},{"title":"Break","time":"18:40 \u2013 19:00 CET","speaker":"","day":"do","start":"18:40:00","minutes":160},{"title":"Why should we mind the intention-action gap in guideline implementation?","time":"19:00 \u2013 19:10","speaker":"Kanumilli N (Manchester, UK)  ","day":"do","start":"19:00:00","minutes":180},{"title":"Deciphering guidelines \u2013 One voice on cardiorenal protection","time":"19:10 \u2013 19:25","speaker":"Cheng A (Mississauga, Canada)","day":"do","start":"19:10:00","minutes":190},{"title":"Screening for CKD in PCP clinic","time":"19:25 \u2013 19:40","speaker":"Rossing P (Copenhagen, Denmark) ","day":"do","start":"19:25:00","minutes":205},{"title":"Never walk alone \u2013 Become a Guardian","time":"19:40 \u2013 19:50","speaker":"Kanumilli N (Manchester, UK)  ","day":"do","start":"19:40:00","minutes":220},{"title":"Q&A, Summary and Closing","time":"19:50 \u2013 20:00","speaker":"Cheng A (Mississauga, Canada) ","day":"do","start":"19:50:00","minutes":230},{"title":"The Virtual CVOT Summit 2022 continues tomorrow, Friday November 11, at 08:30 CET. We look forward to your participation!","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"The Virtual CVOT Summit 2022 continues tomorrow, Friday November 11, at 08:30 CET. We look forward to your participation!","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"The livestream will start today at at 08:30 CET.","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"Further merging new glycemic markers with outcomes in diabetes","time":"08:30 \u2013 08:45","speaker":"Battelino T (Ljubljana, Slovenia)","day":"fr","start":"08:30:00","minutes":0},{"title":"Combination therapy: When is the right time for insulin?","time":"08:45 \u2013 09:00","speaker":"Giorgino F (Bari, Italy)","day":"fr","start":"08:45:00","minutes":15},{"title":"Inhaled Insulin: Initiation and titration to improve time in range","time":"09:00 \u2013 09:25 ","speaker":"Pettus J (San Diego, US), Edelman S (San Diego, US)","day":"fr","start":"09:00:00","minutes":30},{"title":"Discussion","time":"09:25 \u2013 09:45 ","speaker":"","day":"fr","start":"09:25:00","minutes":55},{"title":"CKD: The importance of Real World Evidence (RWE) in clinical decision making ","time":"09:45 \u2013 10:00 ","speaker":"Pecoits-Filho R (Curitiba, Brasil)","day":"fr","start":"09:45:00","minutes":75},{"title":"Real world evidence in CVD: strengths and weaknesses","time":"10:00 \u2013 10:15","speaker":"Kanumilli N (Manchester, UK)  ","day":"fr","start":"10:00:00","minutes":90},{"title":"OP 1: Risk of stroke in patients with Type 2 Diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: A real-world US claims database analysis ","time":"10:15 \u2013 10:25","speaker":"Evans M (Cardiff, UK)","day":"fr","start":"10:15:00","minutes":105},{"title":"Discussion","time":"10:25 \u2013 10:30","speaker":"","day":"fr","start":"10:25:00","minutes":115},{"title":"Break","time":"10:30 \u2013 11:00 CET","speaker":"","day":"fr","start":"10:30:00","minutes":120},{"title":"Treatment of CKD: SGLT-2-inhibitors and future developments","time":"11:00 \u2013 11:15","speaker":"Heerspink H (Groningen, Netherlands) ","day":"fr","start":"11:00:00","minutes":150},{"title":"GLP-1 RAs moving towards CKD: An update","time":"11:15 \u2013 11:30","speaker":"Nauck M (Bochum, Germany)","day":"fr","start":"11:15:00","minutes":165},{"title":"Management of CKD in diabetes - Targeting unmet needs","time":"11:30 \u2013 11:45","speaker":"Groop PH (Helsinki, Finland)","day":"fr","start":"11:30:00","minutes":180},{"title":"New treatment options for CKD in diabetes: Learnings from recent studies","time":"11:45 \u2013 12:00","speaker":"Hadjadj S (Poitiers, France)","day":"fr","start":"11:45:00","minutes":195},{"title":"Panel Discussion","time":"12:00 \u2013 12:30","speaker":"","day":"fr","start":"12:00:00","minutes":210},{"title":"Break","time":"12:30 \u2013 13:00 CET","speaker":"","day":"fr","start":"12:30:00","minutes":240},{"title":"Monitoring and screening of heart failure in diabetes:  The increasing role of biomarkers","time":"13:00 \u2013 13:20","speaker":"Ceriello A (Milan, Italy)","day":"fr","start":"13:00:00","minutes":270},{"title":"Managing HFpEF with SGLT-2-inhibitors","time":"13:20 \u2013 13:40","speaker":"Solomon S (Boston, US)","day":"fr","start":"13:20:00","minutes":290},{"title":"OP 2: Effectiveness and safety of empagliflozin in routine care: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","time":"13:40 \u2013 13:50 ","speaker":"Htoo PH (Boston, US)","day":"fr","start":"13:40:00","minutes":310},{"title":"OP 3: Plasma mannose as a novel marker of myocardial infarction across different glycaemic states","time":"13:50 - 14:00","speaker":"Fortin E (Stockholm, Sweden)","day":"fr","start":"13:50:00","minutes":320},{"title":"Panel Discussion","time":"14:00 \u2013 14:30 CET ","speaker":"","day":"fr","start":"14:00:00","minutes":330},{"title":"Break","time":"14:30 \u2013 15:00 CET","speaker":"","day":"fr","start":"14:30:00","minutes":360},{"title":"Present and future of weight management in obesity and diabetes","time":"15:00 \u2013 15:20","speaker":"Wilding JPH (Liverpool, UK)","day":"fr","start":"15:00:00","minutes":390},{"title":"Dual GIP\/GLP Agonists: Guidelines and practical considerations in diabetes","time":"15:20 \u2013 15:40 ","speaker":"Davies M (Leicester, UK)","day":"fr","start":"15:20:00","minutes":410},{"title":"Targeting obesity: High-dose GLP1-RAs and dual GIP\/GLP Agonists","time":"15:40 \u2013 16:00 ","speaker":"Vilsb\u00f8ll T (Copenhagen, Denmark)","day":"fr","start":"15:40:00","minutes":430},{"title":"OP 4: Systolic blood pressure reduction with tirzepatide across SURPASS program: A mediation analysis using weight loss as a factor ","time":"16:00 \u2013 16:10","speaker":"Ranta K (Indianapolis, US)","day":"fr","start":"16:00:00","minutes":450},{"title":"Discussion","time":"16:10 \u2013 16:30","speaker":"","day":"fr","start":"16:10:00","minutes":460},{"title":"Industry\u00b4s perspective - panel discussion ","time":"16:30 \u2013 17:30 CET","speaker":"","day":"fr","start":"16:30:00","minutes":480},{"title":"OP 5: Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with Type 2 Diabetes","time":"","speaker":"Rau M (Aachen, Germany)","day":"fr","start":"","minutes":"999999999999999"},{"title":"OP 6: Influence of continuous glucose monitoring on the glycemic control and quality of life in patients with Type 2 Diabetes mellitus and coronary heart disease","time":"","speaker":"Saienko Y (Kyiv, Ukraine)","day":"fr","start":"","minutes":"999999999999999"},{"title":"OP 7: Estimated glomerular filtration rate, mortality and MACE in men with hypogonadism and Type 2 Diabetes under long-term testosterone therapy","time":"","speaker":"Saad F (Berlin, Germany)","day":"fr","start":"","minutes":"999999999999999"},{"title":"OP 8: Investigating the role of small nucleolar RNAs (snoRNAs) as an early genetic marker of future adverse cardiovascular events","time":"","speaker":"Kumar U (Cambridge, UK)","day":"fr","start":"","minutes":"999999999999999"},{"title":"OP 9: Sodium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)","time":"","speaker":"Ferrannini G (Stockholm, Sweden)","day":"fr","start":"","minutes":"999999999999999"},{"title":"Abstract Awards and Closing","time":"18:30 \u2013 18:45 CET ","speaker":"Schnell O (Munich, Germany) ","day":"fr","start":"18:30:00","minutes":600},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"Thank you for your attendance and contribution to the Virtual CVOT Summit 2022. <br\/>See you next year for the 9th CVOT Summit on November 23 - 24, 2023.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"Thank you for your attendance and contribution to the Virtual CVOT Summit 2022. <br\/>See you next year for the 9th CVOT Summit on November 23 - 24, 2023.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"We will be right back.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"We are currently having some technical issues. We will be right back.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"The page is automatically updated.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"The next program item is loaded.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"}]